Dominari (NASDAQ:DOMH - Get Free Report) posted its quarterly earnings results on Monday. The company reported ($1.02) EPS for the quarter, Zacks reports. Dominari had a negative return on equity of 91.67% and a negative net margin of 167.73%.
Dominari Trading Down 7.0%
Shares of NASDAQ:DOMH traded down $0.40 on Monday, hitting $5.33. The company had a trading volume of 308,890 shares, compared to its average volume of 915,819. Dominari has a 1-year low of $0.83 and a 1-year high of $13.58. The stock has a market cap of $78.05 million, a price-to-earnings ratio of -1.18 and a beta of 0.50. The stock has a 50 day moving average price of $5.23 and a 200 day moving average price of $5.28.
Analyst Ratings Changes
Separately, Wall Street Zen cut Dominari from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd.
Read Our Latest Stock Analysis on DOMH
Hedge Funds Weigh In On Dominari
An institutional investor recently raised its position in Dominari stock. Geode Capital Management LLC raised its stake in Dominari Holdings Inc. (NASDAQ:DOMH - Free Report) by 2.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 66,283 shares of the company's stock after purchasing an additional 1,866 shares during the period. Geode Capital Management LLC owned 0.45% of Dominari worth $361,000 at the end of the most recent quarter. Institutional investors and hedge funds own 42.48% of the company's stock.
Dominari Company Profile
(
Get Free Report)
Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dominari, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dominari wasn't on the list.
While Dominari currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.